Quantcast
Home » Money
Home » Money

Initial public offerings scheduled to debut next week

First Published Jul 25 2014 12:25PM      Last Updated Jul 25 2014 12:25 pm

New York • The following is a list of initial public offerings planned for the week of July 28:

Angion Biomedica Corp. - Uniondale, N.Y., 2.7 million shares, priced $10 to $12, managed by Aegis Capital. Proposed Nasdaq Capital Market symbol ANGN. Business: Developing therapies for injured organs that trigger the body’s natural regeneration.

Auris Medical Holding AG - Zug, Switzerland, 6.9 million common shares, priced $10 to $12, managed by Jefferies, and Leerink Partners. Proposed Nasdaq symbol EARS. Business: Biotech developing treatments for tinnitus and other inner ear disorders.

Avalanche Biotechnologies Inc. - Menlo Park, Calif., 5.4 million shares, priced $13 to $15, managed by Jefferies, Cowen, and Piper Jaffray. Proposed Nasdaq symbol AAVL. Business: Early-stage biotech developing a gene therapy for wet AMD.



Bio Blast Pharma Ltd. - Tel Aviv, Israel, 3.3 million ordinary shares, priced $11 to $13, managed by Oppenheimer, and Roth Capital. Proposed Nasdaq Capital Market symbol ORPN. Business: Biotech developing treatments for rare and ultra-rare genetic diseases.

Catalent Inc. - Somerset, N.J., 42.5 million shares, priced $19 to $22, managed by Morgan Stanley, J.P. Morgan, and BofA Merrill Lynch. Proposed NYSE symbol CTLT. Business: Global provider of oral, injectable and respiratory drug delivery technologies.

FCB Financial Holdings Inc. - Weston, Fla., 8.7 million shares, priced $24 to $27, managed by Deutsche Bank, J.P. Morgan, and BofA Merrill Lynch. Proposed NYSE symbol FCB. Business: Consolidation of 54 failed and acquired banks in Miami and coastal Florida.

HealthEquity Inc. - Draper, Utah, 9.1 million shares, priced $10 to $12, managed by J.P. Morgan, and Wells Fargo. Proposed Nasdaq symbol HQY. Business: Offers an integrated platform for managing health savings accounts.

Lantheus Holdings Inc. - North Billerica, Mass., 9.3 million shares, priced $12 to $15, managed by Citigroup, and Jefferies. Proposed Nasdaq symbol LNTH. Business: Sells medical imaging agents used in the diagnosis of cardiovascular diseases.

Loxo Oncology Inc. - Stamford, Conn., 4.4 million shares, priced $12 to $14, managed by Cowen & Co., and Stifel. Proposed Nasdaq symbol LOXO. Business: Biotech developing small molecule therapeutics to treat solid tumors.

Macrocure Ltd. - Petach Tikva, Israel, 5.4 million ordinary shares, priced $13 to $15, managed by Credit Suisse, and Jefferies. Proposed Nasdaq symbol MCUR. Business: Late-stage biotech developing white blood cell injections to treat hard-to-heal wounds.

Marinus Pharmaceuticals Inc. - New Haven, Conn., 4 million shares, priced $12 to $14, managed by Stifel, and JMP Securities. Proposed Nasdaq symbol MRNS. Business: Early-stage biotech developing an add-on therapy for epilepsy.

Mobileye N.V. - Jerusalem, Israel, 27.8 million ordinary shares, priced, $17 to $19, managed by Goldman Sachs, Morgan Stanley, and Deutsche Bank. Proposed NYSE symbol MBLY. Business: Provider of camera-based technology to avoid automobile collisions.

SIRVA Inc. - Oakbrook Terrace, Ill., 11.6 million shares, priced $15 to $17, managed by Morgan Stanley, Goldman Sachs, and J.P. Morgan. Proposed Nasdaq symbol SRVA. Business: Provides domestic and international relocation services for employees.

Synchrony Financial - Stamford, Conn., 125 million shares, priced $23 to $25, managed by Goldman Sachs, J.P. Morgan, and Citigroup. Proposed NYSE symbol SYF. Business: Spinoff of GE’s private label credit card and consumer finance business.

Tobira Therapeutics Inc. - San Francisco, 4.6 million shares, priced $12 to $14, managed by BMO Capital Markets, JMP Securities, and Oppenheimer. Proposed Nasdaq symbol TBRA. Business: Biotech developing an immunotherapy treatment for liver disease (NASH) and HIV.

 

 

» Next page... 2 One page

 

 

comments powered by Disqus